Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

CARMIEL, Israel, Nov. 27, 2020 -- (Healthcare Sales & Marketing Network) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeuti... Biopharmaceuticals, FDA Protalix BioTherapeutics, Fabry disease, pegunigalsidase alfa
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news